Dyslipidemia

Pooled pivotal phase 3 trial data from the ORION program shows the first-in-class therapy's significant benefit and tolerability versus placebo.

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.

Marc Bonaca, MD, discusses the results of the VOYAGER-PAD trial in a special edition ACC House Call with HCPLive.

Data presented at ACC.20/WCC is shedding light on the impact of genotype-guided antiplatelet therapy in patients undergoing PCI for ACS or CAD.

Discussing how approval of bempedoic acid impacts the role of PCSK9 inhibitors for lowering LDL-C.

New findings show eligible men and minority group patients are less likely to receive a fill for the novel drug class.

An open-label extension of GLAGOV shows the monoclonal antibody plus statin therapy is not associated with any new safety concerns.

A special edition ACC House Call with Deepak Bhatt, MD, to discuss the results of a meta-analysis looking at ticagrelor and MALE from 2 clinical trials.

Executive Director of Interventional Cardiovascular Programs at Brigham and Women's discusses some research he took part in being presented at this year's conference.

The author of the first systematic evaluation of commissural alignment in TAVR shares his team's findings.

Data published in NEJM demonstrate the siRNA agent's ability to lower cholesterol in patients with multiple conditions.

About 1 in every 20 adult Americans now reguarly uses vaping and e-cigarette products.

Results of a meta-analysis of more than 2 dozen studies indicate DCB treatment may actually reduce mortality risk long-term.

New data from EPI Lifestyle Conference 2020 is shedding light on the impact of initiating estradiol therapy closer to the onset of menopause.

New data from Brigham and Women's Hospital suggests sleep irregularity could be a risk factor for cardiovascular disease.

A discussion on how to approach the real-world application of bempedoic acid with the Chief of Cardiology at Baylor College of Medicine.

The non-statin, fixed-dose combination therapy received approval less than one week after bempedoic acid received approval for treatment of HeFH.

The approval is the second non-statin LDL-C lowering therapy from Esperion to receive approval in the month of February.

The approval of bempedoic acid (Nexletol) marks the first oral, non-statin therapy approved by the FDA as a lipid-lowering agent in nearly 20 years.

Clinical trial data for the lipid-lowering non-statin agent indicates it can lower LDL-C by as much as 18% when combined with maximally tolerated statins.

Research from the Karolinska Institute indicates ESC/EAS 2019 dyslipidemia guidelines could create an unforeseen financial burden due to new eligibility for PSCK9 class.

New data on the use of polygenic risk scores for predicting certain forms of cardiovascular disease raise questions about the validity of genetic scores in real-world settings.

Analysis using data from the Nurses' Health Study is shedding new light on the interaction of TMAO and coronary heart disease risk.

A pilot study found consumption of cocoa and epicatechin were linked to improved six-minute walking time in PAD patients.

Data from the TAUSSIG study supports the long-term use of evolocumab for the treatment of both phenotypes of hypercholesterolemia.